Eli Lilly & Co. vs. TG Therapeutics, Inc.
Eli Lilly & Co. (LLY) comes out ahead, leading on 2 of 2 compared factors.
Size & Scale
| LLY | TGTX | |
|---|---|---|
| Market Cap | $1.09 trillion | $7.58 billion |
| Revenue (TTM) | — | $799.54 million |
| Net Income (TTM) | — | $441.49 million |
LLY leads on 1 of 1 size & scale factors.
Valuation
| LLY | TGTX | |
|---|---|---|
| P/E Ratio | — | 17.72 |
| Price / Book | — | 12.54 |
| Price / Sales | — | 9.48 |
LLY and TGTX split the valuation factors evenly.
Profitability
| LLY | TGTX | |
|---|---|---|
| Net Margin | — | 55.22% |
| Return on Equity | — | 73.08% |
LLY and TGTX split the profitability factors evenly.
Risk & Sentiment
| LLY | TGTX | |
|---|---|---|
| Short Interest | 1.29% | 11.01% |
LLY leads on 1 of 1 risk & sentiment factors.
Dig deeper: LLY overview, LLY financials, TGTX overview, TGTX financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.